- Time:
2025 was a rollercoaster year for the cell and gene therapy field. Stories such as the successful treatment of ‘Baby KJ’ using a bespoke gene editor developed through a public–private partnership, and the exciting news of a gene therapy breakthrough for Huntington’s disease, bring immense hope for the future of medicine. But the tragic news of patient deaths in high-profile trials for muscular dystrophy and a landmark CRISPR trial using lipid nanoparticles threatens to derail progress and investment just as the biotech sector appeared to be turning around.
In The State of Cell and Gene Therapy—GEN’s first virtual event of 2026—we present a group of outstanding researchers and thought-leaders to discuss the latest advances and challenges in delivering genetic therapies. Among the confirmed speakers are Jennifer Adair, PhD (UMass Chan Medical School); Cecilia Cotta-Ramusino, PhD (Tessera Therapeutics); Ben Hurlbut, PhD (Arizona State University); and Eriona Hysolli, PhD (Manhattan Genomics).
Key topics include:
- The potential of gene writing to address genetic disorders
- Expanding access to cell and gene therapies worldwide
- The promise of in vivo CAR T therapy
- Delivering gene therapies across the blood-brain barrier
- The ethical future of gene editing in human embryos
Registration is free!
Guest Speakers Include
